Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
820 stopped studies mapped to Malignant Colorectal Neoplasm and descendants · 90% state a reason
Over the 820 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT01239095 | Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing… | Phase 1 | terminated | Nov 11, 2010 | Richard Whelan | not stated | Not stated |
| NCT04177602 | Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer… | Phase 1 / Phase 2 | terminated | Nov 26, 2019 | Universitätsklinikum Hamburg-Eppendorf | Due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer… | Sponsor / business decision |
| NCT03791398 | BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC(379) | Phase 1 / Phase 2 | terminated | Jan 2, 2019 | Brown University | Lack of efficacy | Efficacy / futility |
| NCT05730673 | Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal… | Phase 2 | withdrawn | Feb 16, 2023 | CytoDyn, Inc. | No participants enrolled | Enrollment / accrual |
| NCT03678428 | FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially… | Phase 3 | terminated | Sep 19, 2018 | Sun Yat-sen University | Production halt of FUDR in China | Other (stated, no rule matched) |
| NCT04150705 | PET/MR for Rectal Cancer Treatment Monitoring and Surveillance | N/A | terminated | Nov 5, 2019 | Washington University School of Medicine | It was determined that the trial could stop early due to surpassing the feasibility rate. | Other (stated, no rule matched) |
| NCT03249727 | Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects…(ANKA-HR) | N/A | terminated | Aug 15, 2017 | ATGen Canada Inc | Recruiting issues | Enrollment / accrual |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT01952730 | Pilot Study of GVAX in Colorectal Cancer Cells | Phase 1 | terminated | Sep 30, 2013 | Massachusetts General Hospital | Slow Accrual | Enrollment / accrual |
| NCT02910843 | Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in…(RECAP) | Phase 1 | terminated | Sep 22, 2016 | Swiss Cancer Institute | due to structural financial deficit of SAKK | Funding |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E… | Phase 1 | terminated | Aug 5, 2019 | University of California, San Francisco | Sponsor funding | Funding |
| NCT05368688 | Microbiome in Colorectal Cancer Onset and Progression | — | terminated | May 10, 2022 | Viome | Recruitment rate was too low to continue the study. | Enrollment / accrual |
| NCT01882660 | Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study(DECO) | N/A | terminated | Jun 20, 2013 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Inclusion of patients was slow. Could not reach the target within the studyperiod. | Other (stated, no rule matched) |
| NCT05291988 | A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural… | N/A | terminated | Mar 23, 2022 | Fred Hutchinson Cancer Center | Terminated due to low accrual | Enrollment / accrual |
| NCT02700555 | Surveillance of Metabolic Parameters in Patients With Colorectal Cancer(SPRING) | — | terminated | Mar 7, 2016 | Kangbuk Samsung Hospital | The patient's study enrollment was too low. | Enrollment / accrual |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | Phase 1 | terminated | May 8, 2015 | Amgen | not stated | Not stated |
| NCT02597075 | Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative… | N/A | terminated | Nov 4, 2015 | Swiss Cancer Institute | Feasibility (low patient accrual and financial reasons) | Enrollment / accrual |
| NCT05178576 | A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage… | Phase 2 | withdrawn | Jan 5, 2022 | NSABP Foundation Inc | Study drug not available for the study duration. | Other (stated, no rule matched) |
| NCT05433402 | Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for… | Phase 1 / Phase 2 | withdrawn | Jun 27, 2022 | Sadat City University | Organizational safety isues | Safety / toxicity |
| NCT00954876 | Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic… | Phase 2 | withdrawn | Aug 7, 2009 | Translational Genomics Research Institute | Study halted prematurely, prior to enrollment of first participant | Enrollment / accrual |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT03827044 | Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE…(POLEM) | Phase 3 | terminated | Feb 1, 2019 | Royal Marsden NHS Foundation Trust | POLEM encountered significant recruitment challenges. With little prospect of recruiting to target… | Enrollment / accrual |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | Phase 2 | terminated | Dec 20, 2018 | Fred Hutchinson Cancer Center | Terminated due to expiration of funding | Funding |
| NCT04372992 | The Stoma Closure Before or After Adjuvant Therapy Trial(STOMAD) | N/A | terminated | May 4, 2020 | Ospedale Umberto I di Torino | Low accrual - no restart after pandemic suspension | COVID-19 / pandemic |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT05018325 | Assessing Effect of Withdrawal Time on Adenoma Detection Rate for Screening Colonoscopy | N/A | terminated | Aug 24, 2021 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT00936832 | Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients… | Phase 2 | withdrawn | Jul 10, 2009 | Federation Francophone de Cancerologie Digestive | because the sunitinib showed futility in anotehr trial | Efficacy / futility |
| NCT04632199 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent… | Phase 1 | withdrawn | Nov 17, 2020 | Ipsen | Business decision not related to any safety or tolerability concern | Safety / toxicity |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT02960282 | Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing… | — | terminated | Nov 9, 2016 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT03524820 | Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer | Phase 2 | terminated | May 15, 2018 | Hadassah Medical Organization | By Merck | Other (stated, no rule matched) |
| NCT02300922 | Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer(RITCOLON) | Phase 1 / Phase 2 | terminated | Nov 25, 2014 | Nantes University Hospital | Premature termination of recruitment due to the discontinuation of product supply by the project's… | Drug supply |
| NCT04685551 | Improving Survivorship Among Minority Cancer Dyads | N/A | withdrawn | Dec 28, 2020 | Charles Drew University of Medicine and Science | Study not funded | Funding |
| NCT04670588 | Response Assessment by Circulating Tumor DNA in Patients With Locally Advanced Rectal… | — | withdrawn | Dec 17, 2020 | Medical College of Wisconsin | No accrual. | Enrollment / accrual |
| NCT02445456 | Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer(SentiRect) | N/A | terminated | May 15, 2015 | Oxford University Hospitals NHS Trust | Logistical difficulties in recruiting patients led to slower than expected recruitment. Recruitment… | COVID-19 / pandemic |
| NCT01759238 | Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer(OLGA) | Phase 2 | terminated | Jan 3, 2013 | Universitätsklinikum Hamburg-Eppendorf | unexpectedly slow recruitment | Enrollment / accrual |
| NCT03970694 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally… | Phase 3 | terminated | May 31, 2019 | Sun Yat-sen University | Significant differences in conversion rate as well as R0 resection rate between the two groups. | Other (stated, no rule matched) |
| NCT02837159 | A Mobile Aplication for the Promotion of Healthy Lifestyle Habits in Patients With… | N/A | withdrawn | Jul 19, 2016 | Universidad de Granada | removal of the Phd student due to not obtaining financing | Funding |
| NCT03475680 | Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery(COLONPREP) | Phase 3 | terminated | Mar 23, 2018 | Assistance Publique - Hôpitaux de Paris | lack of inclusions | Other (stated, no rule matched) |
| NCT01507545 | Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) | Phase 2 | terminated | Jan 11, 2012 | Morphotek | By the sponsor at the end of Stage 1 due to futility. | Efficacy / futility |
| NCT02423785 | Ocular Blood Flow in Colorectal Cancer Patients | — | terminated | Apr 22, 2015 | Medical University of Vienna | Slow recruitment | Enrollment / accrual |
| NCT05156463 | The PAI Trial for Breast and Colon Cancer Survivors | N/A | withdrawn | Dec 14, 2021 | Milton S. Hershey Medical Center | Award not yet received and PI is transferring to a different institution | Other (stated, no rule matched) |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT04627142 | A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People… | Phase 1 | terminated | Nov 13, 2020 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT02588248 | L-Menthol Injection as a Novel Technique During Colonoscopy(MINT-C) | Phase 3 | terminated | Oct 27, 2015 | University Hospitals Cleveland Medical Center | Sponsor/Investigator has decided to close out the study | Investigator |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 23, 2023source: clinicaltrials